全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Hitomi Mori , Makoto Kubo , Masaya Kai ...
来源:[J].Clinical Breast Cancer(IF 2.422), 2018Elsevier
摘要:Abstract(#br)Background(#br)The inexpensive prediction of the characteristics of BRCA -mutated breast cancer as “BRCAness” using the somatic cells of patients with breast cancer could be useful for developing a therapeutic strategy. Our objective was to correlate BRCAness...
作者:M. T. Branham , E. Campoy , S. Laurito ...
来源:[J].Breast Cancer Research and Treatment(IF 4.469), 2016, Vol.155 (1), pp.13-23Springer
摘要:Abstract(#br)BRCAness breast tumors represent a group of sporadic tumors characterized by a reduction in BRCA1 gene expression. As BRCA1 is involved in double-strand breaks (DSBs) repair, dysfunctional BRCA pathway could make a tumor sensitive to DNA damaging drugs (e.g., platinu...
作者:Hitomi Mori , Makoto Kubo , Reiki Nishimura ...
来源:[J].PLoS ONE(IF 3.73), 2017, Vol.11 (12)DOAJ
摘要:... In this study, we assessed BRCAness, defined as the shared characteristics between sporadic and BRCA1-mutated tumors, in a large cohort of TNBC cases.The BRCAness of 262 patients with primary TNBCs resected between January 2004 and December 2014 was determined through the iso...
作者:Tian Tian , Ling Shan , Wentao Yang ...
来源:[J].Human Pathology(IF 2.843), 2018Elsevier
摘要:Summary(#br)Some sporadic triple-negative breast cancers (TNBCs) share similar clinicopathologic and molecular characteristics with BRCA1/2 -mutant breast cancers, a phenotype described as “BRCAness”. Identifying BRCAness in TNBCs could expand the target group for platin...
作者:Hollis RL , Churchman M , Gourley C
来源:[J].OncoTargets and Therapy(IF 2.073), 2017, Vol.Volume 10, pp.2539-2551DOAJ
摘要:... BRCA1- and BRCA2-associated OCs have historically been described as a single subgroup of OC that displays a distinct set of characteristics termed the “BRCAness” phenotype. The hallmarks of this phenotype are superior clinical outcome and hypersensitivity to platinum-ba...
作者:T. Ishikawa , K. Narui , M. Tanabe ...
来源:[J].European Journal of Surgical Oncology(IF 2.614), 2016, Vol.42 (7), pp.999-1001Elsevier
摘要:Abstract(#br)Aim(#br)Triple negative breast cancer (TNBC) is a heterogeneous disease and is associated with the cancer stem cell (CSC), basal-like, and BRCA1 function deficient (BRCAness) subtypes. We examined these 3 subtypes in TNBC and compared their chemosensitivity against a...
作者:Min Zhang , Guoyan Liu , Fengxia Xue ...
来源:[J].Gynecologic Oncology(IF 3.929), 2016, Vol.141 (1), pp.57-64Elsevier
摘要:...(#br)Methods(#br)BRCAness status was defined by analyzing whole-exome deep sequencing data from 220 BRCAwt OvCa cases in TCGA. Thirty-three DNA-repair genes were screened in an integrated manner for BRCA-independent mechanism of BRCAness using multiple-dimensional genomic...
作者:Sadako Akashi-Tanaka , Chie Watanabe , Tomoko Takamaru ...
来源:[J].Clinical Breast Cancer(IF 2.422), 2015, Vol.15 (1), pp.80-85Elsevier
摘要:...(#br)Patients and Methods(#br)We retrospectively investigated BRCAness in 73 patients with breast cancer who had been treated with taxane- and/or anthracycline-based neoadjuvant chemotherapy (NAC). Using multiplex, ligation-dependent probe amplification on formalin-fixed cor...
作者:Weiya Z Wysham , Paulette Mhawech-Fauceglia , Hong Li ...
来源:[J].PLoS ONE(IF 3.73), 2018, Vol.7 (1)DOAJ
摘要:... We hypothesize that a subset of sporadic ovarian carcinomas may harbor anomalies in HR pathways, and that a BRCAness profile (defects in HR or other DNA repair pathways) could influence response rate and survival after treatment with platinum drugs. Clinical availability of a...
作者:Rosa Murria Estal , Sarai Palanca Suela , Inmaculada de Juan Jiménez ...
来源:[J].Familial Cancer(IF 1.935), 2016, Vol.15 (2), pp.193-200Springer
摘要:Abstract(#br)The study aims to identify the relevance of immunohistochemistry (IHC), copy number aberrations (CNA) and epigenetic disorders in BRCAness breast cancers (BCs). We studied 95 paraffin included BCs, of which 41 carried BRCA1/BRCA2 germline mutations and 54 were non he...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×